HR and breast cancer: In the absence of ET resistance, either primary or secondary, subsequent treatment options are limited; there are only a few therapy options available for premenopausal women with HR+/HER2- metastatic BC, and these are mostly derived from trials in which postmenopausal patients were enrolled (9).